Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator

被引:0
作者
Alberto Migliore
Emanuele Bizzi
Serena Broccoli
Bruno Laganà
机构
[1] S. Pietro FBF Hospital,Rheumatology
[2] CRO,Rheumatology, 2nd medical school
[3] Bioikos Pharma,undefined
[4] La Sapienza University,undefined
来源
Clinical Rheumatology | 2012年 / 31卷
关键词
Placebo; Primary Endpoint; Infliximab; Etanercept; Adalimumab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:193 / 194
页数:1
相关论文
共 40 条
[1]  
Mease PJ(2000)Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 385-390
[2]  
Goffe BS(2005)Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227–36. Erratum in Arthritis Rheum 52 2951-1157
[3]  
Metz J(2005)IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Ann Rheum Dis 64 1150-1050
[4]  
VanderStoep A(2007)Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy J Rheumatol 34 1040-undefined
[5]  
Finck B(undefined)undefined undefined undefined undefined-undefined
[6]  
Burge DJ(undefined)undefined undefined undefined undefined-undefined
[7]  
Antoni CE(undefined)undefined undefined undefined undefined-undefined
[8]  
Kavanaugh A(undefined)undefined undefined undefined undefined-undefined
[9]  
Kirkham B(undefined)undefined undefined undefined undefined-undefined
[10]  
Tutuncu Z(undefined)undefined undefined undefined undefined-undefined